PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Extracts effectively alleviate hepatic steatosis and protect the intestinal barrier in a murine model [PMID:40263842]
As part of the Chang-Wei-Qing formulation combined with PD-1 inhibitor, it helps modulate gut microbiota and restore the intestinal barrier in mice [PMID:39701930]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 34352331 (2021) — Akebia quinata and Akebia trifoliata - a review of phytochemical composition, ethnopharmacological approaches and biological studies. · Journal of ethnopharmacology
- 2.PMID: 40263842 (2025) — Akebia trifoliata extracts attenuate liver injury via gut-liver axis in a murine model of nonalcoholic fatty liver disease with low-grade colitis. · Food research international (Ottawa, Ont.)
- 3.PMID: 39701930 (2024) — Chang-Wei-Qing Combined with PD-1 Inhibitor Alleviates Colitis-Associated Colorectal Tumorigenesis by Modulating the Gut Microbiota and Restoring Intestinal Barrier. · Biological procedures online
- 4.PMID: 25632461 (2014) — Nortriterpene Saponins from Akebia trifoliate. · Natural product communications
- 5.PMID: 38275662